» Articles » PMID: 28389830

Effect of Donor Atom Identity on Metal-binding Pharmacophore Coordination

Overview
Publisher Springer
Specialty Biochemistry
Date 2017 Apr 9
PMID 28389830
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The inhibition and binding of three metal-binding pharmacophores (MBPs), 2-hydroxycyclohepta-2,4,6-trien-1-one (tropolone), 2-mercaptopyridine-N-oxide (1,2-HOPTO), and 2-hydroxycyclohepta-2,4,6-triene-1-thione (thiotropolone) to human carbonic anhydrase II (hCAII) and a mutant protein hCAII L198G were investigated. These MBPs displayed bidentate coordination to the active site Zn(II) metal ion, but the MBPs respond to the mutation of L198G differently, as characterized by inhibition activity assays and X-ray crystallography. The L198G mutation increases the active site volume thereby decreasing the steric pressure exerted on MBPs upon binding, allowing changes in MBP coordination to be observed. When comparing the binding mode of tropolone to thiotropolone or 1,2-HOPTO (O,O versus O,S donor sets), structural modifications of the hCAII active site were shown to have a stronger effect on MBPs with an O,O versus O,S donor set. These findings were corroborated with density functional theory (DFT) calculations of model coordination complexes. These results suggest that the MBP binding geometry is a malleable interaction, particularly for certain ligands, and that the identity of the donor atoms influences the response of the ligand to changes in the protein active site environment. Understanding underlying interactions between a MBP and a metalloenzyme active site may aid in the design and development of potent metalloenzyme inhibitors.

Citing Articles

Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities.

Supuran C J Enzyme Inhib Med Chem. 2022; 37(1):2478-2488.

PMID: 36073149 PMC: 9467601. DOI: 10.1080/14756366.2022.2121393.


Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.

Credille C, Dick B, Morrison C, Stokes R, Adamek R, Wu N J Med Chem. 2018; 61(22):10206-10217.

PMID: 30351002 PMC: 6249039. DOI: 10.1021/acs.jmedchem.8b01363.


A Bioinorganic Approach to Fragment-Based Drug Discovery Targeting Metalloenzymes.

Cohen S Acc Chem Res. 2017; 50(8):2007-2016.

PMID: 28715203 PMC: 5749230. DOI: 10.1021/acs.accounts.7b00242.

References
1.
Puerta D, Schames J, Henchman R, McCammon J, Cohen S . From model complexes to metalloprotein inhibition: a synergistic approach to structure-based drug discovery. Angew Chem Int Ed Engl. 2003; 42(32):3772-4. DOI: 10.1002/anie.200351433. View

2.
Rouffet M, Cohen S . Emerging trends in metalloprotein inhibition. Dalton Trans. 2011; 40(14):3445-54. PMC: 3693469. DOI: 10.1039/c0dt01743d. View

3.
Schuttelkopf A, van Aalten D . PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 8):1355-63. DOI: 10.1107/S0907444904011679. View

4.
Monnard F, Heinisch T, Nogueira E, Schirmer T, Ward T . Human carbonic anhydrase II as a host for piano-stool complexes bearing a sulfonamide anchor. Chem Commun (Camb). 2011; 47(29):8238-40. DOI: 10.1039/c1cc10345h. View

5.
Martin D, Blachly P, Marts A, Woodruff T, de Oliveira C, McCammon J . 'Unconventional' coordination chemistry by metal chelating fragments in a metalloprotein active site. J Am Chem Soc. 2014; 136(14):5400-6. PMC: 4104174. DOI: 10.1021/ja500616m. View